"“We demonstrated, for the first time, a material that remains fibrosis-free when implanted in the body,” says Omid Veiseh, a biomaterials researcher who worked on the project as a postdoc at MIT. “There hasn't been anything like this..." - wrong.
"...In the microencapsulation field, size matters. In tests with the super-alginate, the MIT team used capsules with a diameter of 1.5 millimetres, which it has demonstrated are much less immunogenic than the 0.5-mm capsules that researchers in the diabetes cell-therapy field have conventionally used. But a tripling of the diameter means a nearly 30-fold increase in the volume of each capsule. And given the large number of capsules required to contain the hundreds of millions of ß-cells needed to control a person's diabetes, there are few places in the body where the therapy could be implanted. The capsules probably won't fit under the skin or in another easily retrievable location — and regulatory agencies have insisted, as a safety measure, that any stem-cell-derived diabetes therapy implanted in patients should be fully recoverable."
News 
Market Data 
Discover 
